Junshi Biosciences sees revenue jump amid losses

Junshi Biosciences (HKEX: 1877) announced a 29.67% increase in operating income for the year ended December 31, 2024, reaching RMB 194.83 million compared to RMB 150.25 million in the previous year. This growth was primarily fueled by increased sales of commercialized products, including Toripalimab. Domestic sales revenue of Toripalimab increased by more than 60%. Despite revenue gains, the company reported an operating loss of RMB 133.86 million and a total loss of RMB 135.71 million. Basic loss per share stood at RMB 1.30. The company emphasized its focus on enhancing efficiency and controlling expenses. Total assets amounted to RMB 1,078.19 million with equity attributable to owners of the parent company at RMB 586.01 million.